Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

abdominal obesity

- PMLiVE

Roche to acquire 89bio in a deal worth up to US$3.5bn

With the agreement, Roche will gain a treatment for moderate to severe MASH

- PMLiVE

Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

The drug has been authorised to treat both wild-type and hereditary forms of the disease

- PMLiVE

Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

- PMLiVE

Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

- PMLiVE

Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM

Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

- PMLiVE

Alnylam presents positive late-stage results for RNAi therapeutic in ATTR with cardiomyopathy

Hereditary ATTR and wild-type ATTR are responsible for an estimated 350,000 cases globally

- PMLiVE

Alnylam’s patisiran backed by FDA advisory committee for ATTR cardiomyopathy

Treatment options for the underdiagnosed and rapidly progressive condition are currently limited

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Eli Lilly to acquire Versanis in deal worth over $1.9bn

The deal marks a significant boost to the company’s cardiometabolic disease pipeline

- PMLiVE

Alnylam presents promising results for RNAi therapeutic in Alzheimer’s disease at AAIC

ALN-APP is the first investigational RNAi therapeutic to show gene silencing in the human brain

- PMLiVE

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

Amvuttra is given every three months, compared to every few weeks with existing therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links